Featured Archives - Page 11 of 14

Dec 10 2020

Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast

By Admin|2020-12-09T21:39:40-05:00December 10th, 2020|Featured, Investor News, News|0 Comments

Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began ...

Dec 7 2020

Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing

By Admin|2020-12-06T16:39:08-05:00December 7th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research. The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein. Scientific details of the testing to date will ...

Dec 2 2020

Halberd Corporation’s Covid-19 Technology Recognized by Momentum Observer

By Admin|2020-12-01T19:46:42-05:00December 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ). The article featured Halberd's nasal spray currently under development that could be an effective alternative ...

Dec 1 2020

Halberd Corporation Advisory Board Reorganization Announced

By Admin|2020-11-30T19:45:04-05:00December 1st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 1, 2020 – Halberd Corp. (OTC PINK: "HALB") announces the reorganization of its Scientific Advisory Board. The new Advisory Board will consist of two sub-boards: a multi-disciplined Scientific Advisory Board focused on biomedical issues and a Business Advisory Board focusing on business issues. The two boards will interface on a regular ...

Nov 25 2020

Halberd Corp. CEO Interviewed on Money TV;
Discusses 2020 Accomplishments and Plans

By Admin|2020-11-24T20:59:01-05:00November 25th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV. Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman ...

Nov 19 2020

Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation

By Admin|2020-11-18T19:10:48-05:00November 19th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood. By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects ...

Nov 16 2020

Halberd Corp. CEO Interviewed on Money TV; Discusses New Fluorescent Covid-19 Antibody

By Admin|2020-11-15T17:29:50-05:00November 16th, 2020|Featured, Investor News, News|0 Comments

Mr. Hartman discusses advantages over existing antibodies. Jackson Center, PA, November 16, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided information on Halberd’s new patent pending Covid-19 fluorescent antibody. This should allow for rapid ...

Nov 12 2020

Halberd Corporation Reveals Patent-Pending Fluorescent Antibody’s Wide Role in Covid-19 Detection & Treatment

By Admin|2020-11-11T20:25:36-05:00November 12th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University. The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...

Nov 9 2020

Halberd Corporation Files for Patent Protection on Enhanced Nasal Spray to Prevent Covid-19

By Admin|2020-11-08T20:54:51-05:00November 9th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 9, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, “Nasal Spray to Prevent the Transmission of Covid-19,” discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies. This application builds on, and is ...

Nov 5 2020

Halberd Corp. Develops Second Covid-19 Antibody for Enhanced Nasal Spray and Doubles Performance of New Class of Antibody

By Admin|2020-11-04T20:08:10-05:00November 5th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 5, 2020 – Halberd Corporation (OTC PINK: "HALB") reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray. Additionally, Halberd’s continuing work on its new class of antibody doubles the performance capacity of a ...

Previous 101112 Next